Krilogy Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Krilogy Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$838K	Buy	14,648 +524	+4%	+$28.7K	0.02%	450
2026 Q1	$764K	Sell	14,124 -1,596	-10%	-$93.1K	0.02%	445
2025 Q4	$893K	Buy	15,720 +1,126	+8%	+$61.3K	0.03%	376
2025 Q3	$771K	Buy	+14,594	New	+$835K	0.03%	396
2022 Q4	–	Sell	-8,035	Closed	-$681K	–	389
2022 Q3	$681K	Buy	8,035 +87	+1%	+$7.75K	0.08%	168
2022 Q2	$659K	Buy	+7,948	New	+$633K	0.08%	175

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Krilogy Financial's BMRN Position: Q2 2026 in Review

Krilogy Financial increased its BioMarin Pharmaceuticals (BMRN) stake by 3.7% in Q2 2026, buying an estimated $28.7K and bringing the position to 14,648 shares worth $838K. The position accounts for 0.02% of the portfolio, ranked #450.

Krilogy Financial first reported a position in BMRN in Q2 2022 and has held it in 6 quarters since. The position peaked at $893K in Q4 2025. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Krilogy Financial held 14,648 shares of BioMarin Pharmaceuticals worth $838K as of Q2 2026.
Krilogy Financial bought 524 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $28.7K.
BioMarin Pharmaceuticals made up 0.02% of Krilogy Financial's portfolio in Q2 2026, its #450 holding.
Krilogy Financial first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Krilogy Financial's BioMarin Pharmaceuticals position peaked at $893K in Q4 2025.
562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.